Laboratory aspects of COVID-19. Diagnosis, epidemiology, prognosis of patients.
Authors:
B. Friedecký 1; J. Kratochvíla 2
Authors‘ workplace:
Ústav klinické biochemie a diagnostiky FN Hradec Králové
1; SEKK spol. s r. o., Pardubice
2
Published in:
Klin. Biochem. Metab., 28, 2020, No. 3, p. 97-105
Overview
This review deals with laboratory aspects of pandemic disease COVID-19. Our educational and retrospective work contents the basic knowledge on diagnostics, epidemiology, biochemistry and hematology of biomarkers in this disease. Brief characteristics of methods, results and their clinical interpretations are also the part of this communication. Currently published literature about this theme was the source and inspiration for this work.
Keywords:
SARS-CoV-2 – anti-SARS-CoV-2 – RT-PCR – Serology – routine laboratory tests
Sources
1. Adeli, K. Critical role of laboratory medicine in the global response to the COVID-19 pandemic. Clin. Chem. Lab. Med., 2020, 58/7:1019-1020.
2. Bohn, M. K., Lippi, G., Horvath, A., Sethi, S., Koch, D. et al. Molecular, serological and biochemical diagnosis and monitoring of COVID-19. IFCC taskforce evaluation of the latest evidence. Clin. Chem. Lab. Med., 2020, 58/7:1037-1052.
3. Lippi, G., Simundic, A. H., Plebani, M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019. Clin. Chem. Lab. Med., 2020, 58/7:1070-1076.
4. Odběr klinického materiálu z horních cest dýchacích pro diagnostiku COVID-19. Dostupné na webové adrese: http://www.szu.cz
5. Tang, Y. W., Schmitz, J. E., Persing, D. H., Stratton, C. W. The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges. J Clin. Microbiol., 20, doi:10.1128/JCM.00512-20.
6. Péré, H., Podglajen, I., Wack, M., Flamarion, E., Mirault, T. et al. Nasal swab sampling for SARS-CoV-2: A convenient alternative in time of nasopharyngeal swab shortage. J Clin. Microbiol., 2020, doi:10.1128/JCM.00721-20.
7. Wang, D., Wang, H., Li, S., Ren, T., Cao, Z. et al.The sampling locations are closely related to the positive rate of novel Coronavirus nucleic acid detection. Clin. Lab., 2020, doi:10.7754/Clin.Lab.2020.200431.
8. WHO. Laboratory Biosafety Guidance related to coronavirus disease 2019(COVID-19). May, 13, 2020.
9. Lippi, G., Adeli, K., Ferrari, M., Horvath, A. R., Koch, D. et al. Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC taskforce recommendations. Clin. Chem. Lab. Med., 2020, 58/7:1053-1062.
10. SARS-CoV-2. Diagnostic pipeline. www.finddx.org.
11. SARS- CoV-2. Diagnostic performance criteria. www.finddx.org.
12. Westgard, J., Westgard, S. COVID-19 Testing: Maintaining quality in a state of Emergency. Dostupné na: www.westgard.com
13. Dietzen, D. J. Unleashing the Power of Laboratory Developed Tests: Closing gaps in COVID diagnosis and beyond. J Appl. Lab. Med., 2020, doi:10.1093/jalm/jfaa.077/5827001.
14. Plebani, M., Lippi, G. Molecular diagnostics at the times of SARS-CoV-2 outbreak. Diagnosis, 2020, doi:10.1515/dxx-2020-0050.
15. Greene, D. N. Selecting a SARS-CoV-2/COVID molecular testing for your laboratory. J Appl. Lab. Med., 2020, doi:10.1093/jalm/jfaa076/5827000.
16. Policy for diagnostic tests for Coronavirus Disease-2019 tests during the public heath emergency (revised). Immediately in effect guidance for clinical laboratories, commercial manufacturers, and food and drug administration staff. May 4, 2020 U.S.Departement of Health and Human Service. Dostupné na: www.aacc.org.
17. Loeffelholz, M. J., Tang, Y. W. Laboratory diagnosis of emerging human coronavirus infections -The state of the art. Emerg. Microbes. Infect., 2020, 9, 747-756.
18. Loeffelholz, M. J., Alland, D., Butler-Wu, S. M., Pandey, U., Perno, C. F. et al. Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 test. J Clin. Microbiol., 2020, doi:10.1128/JCM.00926-20.
19. Uhteg, K., Jarreth, J., Richards, M., Howard, C., Morehead, E. et al. Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays. J Clin. Virol., 2020, http://doi.org/10.1016/jcv.2020.104384.
20. CDC 2019. Novel Coronavirus(2019-nCoV) Real-Time RT-PCR Diagnostic Panel. Revision 3. Center for Disease Control and Prevention.Division of Viral Diseases. Atlanta 2020. https://www.fda.gov/media/1349221/download.
21. Perchetti, G. A., Nalla, H. K., Huang, M. L., Zhu, H., Wei, Y. et al. Validation of SARS-CoV-2 detection across multiple specimen type. J Clin. Virol., 2020, https:// doi.org.10.1016/jcv.2020.104438.
22. Nalla, A. K., Často, A. H., Huang, M. L., Perchetti, G. A., Sampoleo, R. et al. Comparative performance of SARS-CoV-2. Detection assays using seven different primers/probe sets and one assay kit. J Clin. Microbiol., 2020, doi:10.1128/JCM.00557-20.
23. Raschke, R. A., Curry, S. C., Glenn, T., Gutierrez, S., Iyengar, S. et al. A bayesian analysis of strategies to rule out COVID-19 using Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR). Arch. Pathol. Lab. Med., 2020, doi:10.5858/arpa.2020-0196-LE
24. LeBlanc, J., Gubbay, J. B., Li, Y., Needle, R., Arneson, S. R. et al. Real-timer PCR-based SARS-CoV-2 detection in Canadian laboratories. J Clin. Virol., 2020, doi:10.1016/jcv.2020.104433.
25. Broughton, J. P., Deng, X., Yu, G., Fasching, C. L., Servellita, V. et al. CRISPR-Cas12 based detection of SARS-CoV-2. Nat. Biotechnol., 2020, doi:10.1038/s41587-020-0513-4.
26. Behrmann, O., Bachmann, I., Spiegel, M., Schramm, M., El-Wahed, A. A. et al. Rapid detection of SARS-CoV-2 by low volume real time single tube reverse transcription recombinant polymerase amplification using and exo probe with an internally linked quencher (exo-IQ). Clin. Chem., 2020, 66/8:1047-1059.
27. Farnsworth, Ch. W., Andersen, N. W. SARS-CoV-2 Serology much hype, little data. Clin. Chem., 2020, 66/7:875-877.
28. Ismail, A. A. Serological tests for COVID-19 antibodies: Limitations must be recognized. Ann. Clin. Biochem., 2020, doi:10.1177/0004563220927053.
29. Padoan, A., Cosma, C., Sciacovelli, L., Faggian, D., Plebani, M. Analytical performance of a chemiluminiscence immunoassay for SARS-CoV-2 IgG/IgM and antibody kinetics. Clin. Chem. Lab. Med., 2020, 58/7:1081-1088.
30. Okba, N. M. A., Mueller, M. A., Li, W., Wang, Ch., Geurtsvan Kessel, Ch. et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. Emerg. Infect. Dis., 2020, doi:10.3201/eid267.200841.
31. Bernasconi, L., Oberle, M., Gisler, V., Ottiger, C., Fankhauser, H. et al. Diagnostic performance of a SARS-CoV-2 IgG/IgM lateral flow immunochromato-graphy assay in symptomatic patients presenting to the emergency department. Clin. Chem. Lab. Med., 2020, http//doi.orf/10.1515/cclm-2020-0635.
32. Sood, N., Simon, P., Ebner, P., Eichner, D., Reynolds, J. et al. Seroprevalence of SARS-CoV-2–specific antibodies among adults in Los Angeles county, California. JAMA 2020, 323/23:2425-2427.
33. Bryan, A., Pepper, G., Wener, M. H., Fink, S. R., Morishima, Ch. et al. Performance characteristics of the Abbott Architect SARS-CoV-2-IgG Assay and Seroprevalence in Boise Idaho. J Clin. Microbiol., 2020, doi:10.1128/JCM 00941-20.
34. Tré-Hardy, M., Wilmet, A., Beukinga, I., Dogné, J. M., Douxfils, J. et al. Validation of a chemiluminiscent assay for specific SARS-CoV-2 antibody. Clin. Chem. Lab. Med., 2020, 58/8:1357-1364.
35. Krátká, Z., Luxová, Š., Malíčková, K., Furst, T., Šimková, H. Testování COVID-19 a co bychom měli mít na paměti. Čas. Lék. Čes., 2020,159:72-77.
36. Plebani, M., Padoan, A., Negrini, D., Carpinteri, D., Sciacovelli, L. Diagnostic performance and thresholds the key to harmonization in serological SARS-CoV-2 assays? Clin. Chim. Acta, 2020, https://doi.org/101015/j.cca.2020.05.050.
37. Egger, M., Bundschuh, Ch., Wiesinger, K., Gabriel, Ch., Clodi, M. et al. Comparison of the Elecsys Anti-SARS-CoV-2 immunoassay with the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies human plasma. Clin. Chim. Acta, 2020, 509:18-21.
38. AACC Smart Brief. Special report. 5. May 2020: FDA Issues Revised Policy on Antibody Tests. Dostupné na: www.aacc.org.
39. AACC. Recommendation for SARS-CoV-2 Serology testing issues. Recommendations on the Use of COVID-19 Antibody Tests. May 18, 2020.
40. Henry, B. M., de Oliveira, M. H. S., Benoit, S., Plebani, M., Lippi, G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chem. Lab. Med., 2020, 58/7:1021-1028.
41. Ferrari, D., Motta, A., Strollo, M., Banfi, G., Locatelli, M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin. Chem. Lab. Med., 2020, 58/7:1095-1099.
42. Frater, J., Zini, G., d’Onofrio, G., Rogers, H. J. COVID-19 and the clinical hematology laboratory. Int. J. Lab. Hematol., 2020, https://doi-org/10.1111/ijlh.13229.
43. Zheng, Y., Zhang, Y., Chi, H., Chen, S., Peng, M. et al. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study. Clin. Chem. Lab. Med., 2020, 58/7:1106-1115.
44. Lippi, G., Plebani, M. Procalcitonin in patients with severe coronavirus disease (COVID-19): A meta-analysis. Clin. Chim. Acta, 2020, 505:190-191.
45. Zanimotto, M., Mion, M. M., Cosma, C., Rinaldi, D., Plebani, M. Presepsin in risk stratification of SARS-CoV-2 patients. Clin. Chim. Acta, 2020, 507:161-163.
46. Von Ahsen, N. Interpretationshilfe zu Laborwerten bei der COVID-19 Erkrangung. Dostupné na: www.dgkl.de
47. Kavsak, P. A., DeWit, K., Worster, A. Emerging key laboratory tests for patiens with COVID-19.Clin. Biochem., 2020, 81:13-14.
48. Mardani, R., Vasmehjani, A. A., Zali, F., Gholami, A., Nasab, S. D. M. et al. Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR. A diagnostic accuracy study. Arch. Acad. Emerg. Med., 2020, Apr: 4:8(1):e43. eCollection.
49. Gaze, D. C. Clinical Utility of Cardiac Troponin Measurement in COVID-19 Infection. Ann. Clin. Biochem., 2020, doi:10.1197(000456322091888.
50. Aggarval, G., Cheruiyot, I., Aggraval, S., Wong, J., Lippi, G. et al. Association of cardiovascular disease with coronavirus disease 2019 (COVID -19) severity. A meta-analysis. Curr. Probl. Cardiol., 2020, doi: 10.1016/j.cpcardiol.2020.100617.
51. Baron, D. H., Franchini, M., Goobie, S. M., Javidroozi, M., Klein, A. A. et al. Patient blood management during the COVID-19 pandemic: A narrative review. Anaesthesia, 2020, doi: 10.1111/anae.15095.
52. Harenberg, J., Favarolo, E. COVID-19 progression of disease and intravascular coagulation, present status and future perspectives. Clin. Chem. Lab. Med., 2020, 58/7:1029-1036.
53. Zhang, Z. L., Hou, I. L., Li, D. T., Li, F. Z. Laboratory findings of COVID-19, a systematic review and meta-analysis. Scand. J Clin. Lab. Invest., 2020, http://doi.org/10.1080/00365513.2020.1768587.
54. Sung, H., Yoo, H. K., Han, M. G., Lee, S. W., Lee, H. et al. Preparedness and rapid implementation of external quality assessment helped quickly increase COVID-19 testing capacity in the Republic of Korea. Clin. Chem., 2020, 66/7:979-981.
Labels
Clinical biochemistry Nuclear medicine Nutritive therapistArticle was published in
Clinical Biochemistry and Metabolism
2020 Issue 3
Most read in this issue
- Laboratory diagnostics of COVID-19
- Vitamin D – prevention and treatment in children and adolescents
- Vitamin D 2019 - standardization and chaos. Miniature model of the presentation of laboratory science at present.
- Vitamin D and cardiovascular disease. What do we know about this in 2020?